Product overview
Retatrutide 30mg/10vials is a sterile lyophilized research peptide supplied at the higher-strength 30mg-per-vial configuration. Retatrutide is a synthetic single-molecule triple agonist at the GLP-1, GIP, and glucagon receptors, and is one of the most-studied recent additions to the incretin-mimetic family in preclinical metabolic research.
Independently assayed by HPLC and MS, and lot-traceable to the source preparation. The 30mg-per-vial format sits between the RT20 (20mg) and RT40 (40mg) configurations for research protocols that require an intermediate working volume.
Mechanism
Retatrutide combines agonism at three distinct receptors that converge on metabolic regulation. GLP-1 receptor activation drives glucose-dependent insulin secretion and reduces gastric emptying. GIP receptor activation has been characterized in preclinical literature for complementary effects on adipocyte handling of nutrient flux. Glucagon receptor activation drives hepatic glucose output and, more relevantly for body-composition endpoints, increases energy expenditure.
The combined agonist profile distinguishes Retatrutide from dual-agonist preparations (such as Tirzepatide, GLP-1 + GIP) and single-agonist preparations (semaglutide-class, GLP-1 alone). Preclinical studies have characterized the molecule for combined effects on glycemic endpoints, body composition, and hepatic-fat-fraction.
Typical research dose range
Published preclinical and early clinical metabolic protocols have used Retatrutide across a range of weekly exposure. Animal-model and early-stage clinical research has used per-administration quantities scaling with body mass, with weekly cycling that mirrors the once-weekly dosing pattern characteristic of the incretin-mimetic class. Researchers should consult source literature for the specific endpoint and model organism.
Stack and pairing
Retatrutide is studied alongside Tirzepatide for receptor-coverage comparison work, and is included in protocols examining combined incretin-axis and hepatic-metabolism endpoints. It is also paired with glutathione preparations in study designs that include redox-balance measurements.
Reconstitution and storage
Reconstitute each vial with 1-3 mL of bacteriostatic water for the target working concentration. Use sterile technique. Once reconstituted, store at 2-8 °C and use within 30 days for best stability.
Lyophilized vials should be kept refrigerated at 2-8 °C until first use. For long-term storage beyond six months, store at -20 °C in the original sealed vial. Avoid repeated freeze-thaw cycles.
Kit contents
- 10 × 30mg vials of lyophilized Retatrutide
- 1 × certificate of analysis (lot-specific)
- 1 × handling and reconstitution insert
Frequently asked questions
Is this product for human consumption?
No. This product is sold strictly for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.
How does Retatrutide differ from Tirzepatide?
Tirzepatide is a dual agonist at the GLP-1 and GIP receptors. Retatrutide is a triple agonist that adds glucagon receptor activity to the same molecule. The added glucagon-axis activity is associated in the preclinical literature with increased energy expenditure on top of the incretin-mediated glycemic and satiety endpoints.
Do you ship internationally?
This SKU ships from our Canadian fulfillment facility to addresses within Canada. International availability varies by region — see our shipping policy for current routing.
What is the shelf life of an unopened vial?
Properly stored at 2-8 °C in the original sealed vial, lyophilized Retatrutide retains potency for 24 months from the date of manufacture. The expiration date is printed on each vial.
